<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01303224</url>
  </required_header>
  <id_info>
    <org_study_id>NAK-04</org_study_id>
    <secondary_id>2010-018300-85</secondary_id>
    <nct_id>NCT01303224</nct_id>
  </id_info>
  <brief_title>Ibodutant for Relief of Irritable Bowel Syndrome With Diarrhoea (IBS-D)</brief_title>
  <acronym>IRIS-2</acronym>
  <official_title>Double-blind, Randomised, Placebo-controlled, Parallel-group Phase II Study to Evaluate the Effect of Oral Ibodutant in Irritable Bowel Syndrome With Diarrhoea (IBS-D).</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Menarini Group</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Menarini Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Irritable Bowel Syndrome with diarrhoea (IBS-D) is a functional gastrointestinal disorder
      characterised by chronic or recurrent abdominal pain or discomfort and diarrhoea. This trial
      aims at the evaluation of the efficacy and safety of the neurokinin type 2 receptor
      antagonist Ibodutant in improving IBS-D symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study evaluates the efficacy and safety of three doses of ibodutant, given once daily for
      8 weeks versus placebo in IBS-D patients. Efficacy is evaluated in terms of overall symptom
      relief and abdominal pain/discomfort relief after 8 weeks of treatment. The clinical phase of
      the study comprises a 2-week run-in period (treatment-free),an 8-week double-blind treatment
      period and a 2-week treatment withdrawal period, resulting in a 10-week overall duration of
      the study for each patient.

      Patients report their IBS-related symptoms daily in an electronic diary (web-and telephone
      based)during all periods of the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With Satisfactory Relief During 8 Weeks of Treatment (75% Rule); Intention-to-treat (ITT).</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Weekly binary questions (yes/no) from Interactive Voice/Web Response (IV/WRS) diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 4 Weeks With Satisfactory Relief During 8 Weeks of Treatment (50% Rule) in the ITT Population</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 4/8 weeks with at least 2 consecutive weeks of satisfactory relief during Week 5 to Week 8(50% rule)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Changes (Using EuroQoL EQ-5D Questionnaire)</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Change in EQ-5D Quality of Life (visual analogue scale) score at the end of 8 weeks of treatment versus baseline (at randomisation). EQ-5D quality of life visual analogue scale ranges from &quot;0&quot;= worst imaginable health state to &quot;100&quot;=best imaginable health state.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Subgroup Analysis: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort According to the 75% Rule in the Female ITT Population</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
  </other_outcome>
  <other_outcome>
    <measure>Subgroup Analysis: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort According to the 75% Rule in the Male ITT Population</measure>
    <time_frame>Eight weeks</time_frame>
    <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">565</enrollment>
  <condition>Irritable Bowel Syndrome With Diarrhea</condition>
  <arm_group>
    <arm_group_label>Ibodutant low dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet, to be given once daily in fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibodutant intermediate dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet, to be given once daily in fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibodutant high dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral tablet, to be given once daily in fasting conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Oral tablet, to be given once daily in fasting conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibodutant</intervention_name>
    <description>Oral tablet, low dose, once daily, for 8 weeks</description>
    <arm_group_label>Ibodutant low dose</arm_group_label>
    <other_name>Code: MEN 15596</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibodutant</intervention_name>
    <description>Oral tablet, intermediate dose, once daily, for 8 weeks</description>
    <arm_group_label>Ibodutant intermediate dose</arm_group_label>
    <other_name>Code: MEN 15596</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibodutant</intervention_name>
    <description>Oral tablet, high dose, once daily, for 8 weeks</description>
    <arm_group_label>Ibodutant high dose</arm_group_label>
    <other_name>Code: MEN 15569</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        At start of the run-in period:

          -  Male or female patients aged 18 - 70 years with a clinical diagnosis of IBS-D
             according to the Rome III criteria:

          -  Recurrent abdominal pain/discomfort for at least 3 days per month in the last 3 months
             associated with at least 2 of the following characteristics:

               1. improvement with defecation;

               2. onset associated with a change in the frequency of stool;

               3. onset associated with a change in form (appearance) of stool.

          -  Symptom-onset at least 6 months prior to diagnosis.

          -  Loose/watery stools at least 25% of the time in the last 3 months AND hard/lumpy
             stools less than 25% of the time in the last 3 months.

          -  More than 3 bowel movements per day at least 25% of the time in the last 3 months.

          -  For patients older than 50 years OR patients with positive family history of
             colorectal cancer: Normal results from colonoscopy or flexible sigmoidoscopy.

          -  Mentally competent, able to give written informed consent.

          -  For women of childbearing potential: Use of a highly effective contraceptive method
             throughout the entire study period and up to 30 days post-treatment.

          -  Normal physical examination or without clinically relevant abnormalities.

        At randomisation:

        -Confirmation of IBS-D severity in terms of bowel movement frequency and abdominal pain
        intensity along the 2-week run-in period.

        Exclusion criteria:

          -  Organic abnormalities of the gastrointestinal tract, including history of colonic or
             major abdominal surgery.

          -  History of gluten enteropathy.

          -  Lactose intolerance as assessed by response to diet.

          -  History of positive tests for ova or parasites, or occult blood in the stool.

          -  Previous diagnosis of diabetes mellitus (either type 1 or 2).

          -  Unstable medical condition.

          -  Major psychiatric, neurological, or cardiovascular disorders, or uncontrolled
             metabolic disease.

          -  Relevant changes in dietary habits, lifestyle, or exercise regimen in the previous 2
             months.

          -  Use of concurrent medication with drugs known to interfere with gastro-intestinal
             motility or sensitivity.

          -  Pregnancy or breastfeeding.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Tack, Professor</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>MHAT &quot;Haskovo&quot;, Second Internal Department</name>
      <address>
        <city>Haskovo</city>
        <zip>6300</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Dr. Georgi Stranski&quot;, Clinic of Gastroenterology</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Kaspela&quot;, Department of Gastroenterology</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Sveti Georgi&quot;, Internal Consultative Department</name>
      <address>
        <city>Plovdiv</city>
        <zip>4000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Ruse&quot;, Clinic of Gastroenterology</name>
      <address>
        <city>Ruse</city>
        <zip>7002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fifth City Hospital, Gastroenterology Department</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;Alexandrovska&quot;, Clinic of Propedeutic of Internal Disease</name>
      <address>
        <city>Sofia</city>
        <zip>1431</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Sveta Anna&quot;, Department of Gastroenterology, Endocrinology, and Nephrology</name>
      <address>
        <city>Sofia</city>
        <zip>1784</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMHAT &quot;St. Marina&quot;, Clinic of Gastroenterology</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MHAT &quot;Dr. Stefan Cherkezov&quot;, Gastroenterology Department</name>
      <address>
        <city>Veliko Tarnovo</city>
        <zip>5000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Poliklinika III, Hepato-Gastroenterologie HK</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 12</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastromedic s.r.o., Soukroma ordinace</name>
      <address>
        <city>Pardubice</city>
        <zip>530 02</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IKEM, Klinika hepatogastroenterologie</name>
      <address>
        <city>Prague</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Slany, Internal Department</name>
      <address>
        <city>Slany</city>
        <zip>274 51</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>District Hospital, Internal Department</name>
      <address>
        <city>Strakonice</city>
        <zip>386 29</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Hospital Tabor, Gastroenterology</name>
      <address>
        <city>Tabor</city>
        <zip>390 03</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kojecký Soukroma Ordinace</name>
      <address>
        <city>Zlin</city>
        <zip>76005</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Aalborg</name>
      <address>
        <city>Aalborg</city>
        <zip>9000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Ballerup</name>
      <address>
        <city>Ballerup</city>
        <zip>2750</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gentofte Hospital, Medicinsk Afdeling F</name>
      <address>
        <city>Hellerup</city>
        <zip>2900</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regionshospitalet Silkeborg, Medicinsk Afdeling F</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCBR Vejle</name>
      <address>
        <city>Vejle</city>
        <zip>7100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinische Forschung Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitätsklinik Köln, Gastroenterologie</name>
      <address>
        <city>Cologne</city>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ABX-CRO Clinical Research GmbH</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Private Practice Dr. Schaefer</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>22143</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Israelitisches Krankenhaus, Innere Medizin</name>
      <address>
        <city>Hamburg</city>
        <zip>22297</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gemeinschaftspraxis Kuchta, Wegner, Schiefke</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis Prof. Kellner</name>
      <address>
        <city>Munich</city>
        <zip>80639</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Valduce, Unità Operativa Complessa di Gastroenterologia</name>
      <address>
        <city>Como</city>
        <zip>22100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Anna, U.O. Di Gastroenterologia</name>
      <address>
        <city>Ferrara</city>
        <zip>44100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria Careggi, USOD Gastroenterologia 1</name>
      <address>
        <city>Florence</city>
        <zip>50134</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Università degli Studi di Genova, Dipartimento di Medicina Interna e Specialità Mediche</name>
      <address>
        <city>Genoa</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera - Università di Padova, Struttura Operativa Complessa di Gastroenterologia</name>
      <address>
        <city>Padua</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Policlinico San Matteo, Dipartimento di Medicina Interna I e Gastroenterologia</name>
      <address>
        <city>Pavia</city>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Ospedale Nuovo Santa Chiara-Cisanello, Dipartimento di Medicina Interna</name>
      <address>
        <city>Pisa</city>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Istituto Clinico Humanitas, Dipartimento di Gastroenterologia</name>
      <address>
        <city>Rozzano</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS Ospedale Casa Sollievo della Sofferenza, Divisione di Gastroenterologia</name>
      <address>
        <city>San Giovanni Rotondo</city>
        <zip>71013</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Specjalistyczne Centrum Gastrologii &quot;Gastromed&quot;</name>
      <address>
        <city>Białystok</city>
        <zip>15-531</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im dr Jana Biziela w Bydgoszczy</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gabinet Lekarski Janusz Rudziński</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-681</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mazowieckie Centrum Badań Klinicznych I.Czajkowska M.Śmietańska s.c.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Specjalistyczne Centrum Medyczne &quot;NOWOMED&quot;</name>
      <address>
        <city>Krakov</city>
        <zip>30-349</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>5 Wojskowy Szpital Kliniczny z Polikliniką SPZOZ w Krakowie</name>
      <address>
        <city>Krakov</city>
        <zip>30-901</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Krakowskie Centrum Medyczne</name>
      <address>
        <city>Krakov</city>
        <zip>31-501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instytut Medycyny Wsi im. Witolda Chodźki Publiczny Zakład Opieki Zdrowotnej</name>
      <address>
        <city>Lublin</city>
        <zip>20-090</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Centrum Alergologii&quot;</name>
      <address>
        <city>Lublin</city>
        <zip>20-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Solumed</name>
      <address>
        <city>Poznań</city>
        <zip>60-539</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Zaspół Poradni Specjalistycznych &quot;Artmed&quot;</name>
      <address>
        <city>Poznań</city>
        <zip>60-547</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endoskopia Sp. z o.o.</name>
      <address>
        <city>Sopot</city>
        <zip>81-756</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ &quot;Nasz Lekarz&quot; Praktyka Grupowa Lekarzy Rodzinnych</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Remedis Sp z o.o.</name>
      <address>
        <city>Toruń</city>
        <zip>87-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badawcze Współczesnej Terapii, Prywatny Gabinet Lekarski</name>
      <address>
        <city>Warsaw</city>
        <zip>01-377</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne &quot;Osteomed&quot; Sp. z o. o</name>
      <address>
        <city>Warsaw</city>
        <zip>02-341</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centralny Szpital Kliniczny MSWiA</name>
      <address>
        <city>Warsaw</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NZOZ Vivamed</name>
      <address>
        <city>Warsaw</city>
        <zip>03-580</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol, Digestive Unit</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Teknon, Gastroenteloroly Service</name>
      <address>
        <city>Barcelona</city>
        <zip>08022</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>&quot;Hospital Universitario Virgen de la Arrixaca, Servicio de Medicina del Aparato Digestivo</name>
      <address>
        <city>El Palmar (Murcia)</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico San Carlos, Digestive Diseases</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Mataró, Unitat d'Exploracions Funcionals Digestives</name>
      <address>
        <city>Mataró</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Corporació Sanitària Parc Tauli</name>
      <address>
        <city>Sabadell</city>
        <zip>08208</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago, Gastroenterology</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen Macarena, Digestive Service</name>
      <address>
        <city>Sevilla</city>
        <zip>41009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sahlgrenska Universitetssjukhuset, Mag-tarm lab</name>
      <address>
        <city>Gothenburg</city>
        <zip>413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Probare</name>
      <address>
        <city>Lund</city>
        <zip>223 61</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kärnsjukhuset</name>
      <address>
        <city>Skövde</city>
        <zip>541 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrocentrum Aleris specialistvård Sabbatsberg,</name>
      <address>
        <city>Stockholm</city>
        <zip>113 82</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Akademiska sjukhuset, Gastromottagningen</name>
      <address>
        <city>Uppsala</city>
        <zip>751 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Support, S-huset, Södra Grev Rosengatan</name>
      <address>
        <city>Örebro</city>
        <zip>703 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bulgaria</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 23, 2011</study_first_submitted>
  <study_first_submitted_qc>February 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <results_first_submitted>January 10, 2013</results_first_submitted>
  <results_first_submitted_qc>March 21, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 25, 2013</results_first_posted>
  <last_update_submitted>September 22, 2015</last_update_submitted>
  <last_update_submitted_qc>September 22, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 7, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Irritable Bowel Syndrome</keyword>
  <keyword>Colon, irritable</keyword>
  <keyword>Bowel disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Diarrhea</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First subject screened 06/10/2010, first subject randomised 22/10/2010, last subject out 11/05/2012, at 78 study sites in 8 European countries (Bulgaria, Czech Republic, Denmark, Germany, Italy, Poland, Spain, and Sweden)</recruitment_details>
      <pre_assignment_details>A run-in period was planned to confirm eligibility criteria. 5 more patients were randomized instead of the planned number (560) because due to the high screen fail rate it was impossible to predict with how many patients the enrollment goal would be reached. Although the enrollment goal was reached these 5 patients in screening continued the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ibodutant 1 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="P2">
          <title>Ibodutant 3 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="P3">
          <title>Ibodutant 10 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="P4">
          <title>Placebo</title>
          <description>oral tablet, once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="141">randomised, safety population, &gt;= 1 dose of study medication</participants>
                <participants group_id="P2" count="142">randomised, safety population, &gt;= 1 dose of study medication</participants>
                <participants group_id="P3" count="139">randomised, safety population, &gt;= 1 dose of study medication</participants>
                <participants group_id="P4" count="143">randomised, safety population, &gt;= 1 dose of study medication</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>Intention To Treat</title>
              <participants_list>
                <participants group_id="P1" count="140">subjects with at least 1 primary endpoint evaluation post randomisation</participants>
                <participants group_id="P2" count="138">subjects with at least 1 primary endpoint evaluation post randomisation</participants>
                <participants group_id="P3" count="139">subjects with at least 1 primary endpoint evaluation post randomisation</participants>
                <participants group_id="P4" count="142">subjects with at least 1 primary endpoint evaluation post randomisation</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="130"/>
                <participants group_id="P2" count="131"/>
                <participants group_id="P3" count="133"/>
                <participants group_id="P4" count="133"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibodutant 1 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B2">
          <title>Ibodutant 3 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B3">
          <title>Ibodutant 10 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B4">
          <title>Placebo</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="140"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="139"/>
            <count group_id="B4" value="142"/>
            <count group_id="B5" value="559"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.9" spread="13.7"/>
                    <measurement group_id="B2" value="47.1" spread="13.4"/>
                    <measurement group_id="B3" value="47.0" spread="12.8"/>
                    <measurement group_id="B4" value="44.1" spread="14.0"/>
                    <measurement group_id="B5" value="46.0" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="89"/>
                    <measurement group_id="B2" value="87"/>
                    <measurement group_id="B3" value="79"/>
                    <measurement group_id="B4" value="78"/>
                    <measurement group_id="B5" value="333"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="51"/>
                    <measurement group_id="B3" value="60"/>
                    <measurement group_id="B4" value="64"/>
                    <measurement group_id="B5" value="226"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since onset of IBS symptoms</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.2" spread="7.3"/>
                    <measurement group_id="B2" value="6.3" spread="7.5"/>
                    <measurement group_id="B3" value="6.3" spread="6.9"/>
                    <measurement group_id="B4" value="4.6" spread="6.2"/>
                    <measurement group_id="B5" value="5.8" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IBS symptoms at baseline/ randomisation)</title>
          <description>5 point scale ranging from &quot;0&quot;= no symptoms to &quot;4&quot;= very severe</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Abdominal pain score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="0.6"/>
                    <measurement group_id="B2" value="2.3" spread="0.5"/>
                    <measurement group_id="B3" value="2.3" spread="0.5"/>
                    <measurement group_id="B4" value="2.3" spread="0.6"/>
                    <measurement group_id="B5" value="2.3" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bloating score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.4" spread="0.8"/>
                    <measurement group_id="B2" value="2.2" spread="0.7"/>
                    <measurement group_id="B3" value="2.2" spread="0.7"/>
                    <measurement group_id="B4" value="2.2" spread="0.6"/>
                    <measurement group_id="B5" value="2.3" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urgency score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.5" spread="0.7"/>
                    <measurement group_id="B2" value="2.5" spread="0.6"/>
                    <measurement group_id="B3" value="2.4" spread="0.6"/>
                    <measurement group_id="B4" value="2.4" spread="0.6"/>
                    <measurement group_id="B5" value="2.4" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IBS symptom severity rate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.7" spread="0.7"/>
                    <measurement group_id="B2" value="2.6" spread="0.6"/>
                    <measurement group_id="B3" value="2.6" spread="0.6"/>
                    <measurement group_id="B4" value="2.6" spread="0.6"/>
                    <measurement group_id="B5" value="2.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stool frequency/day</title>
          <description>Overall stool frequency per day</description>
          <units>bowel movements/day</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.6" spread="1.5"/>
                    <measurement group_id="B2" value="4.4" spread="1.3"/>
                    <measurement group_id="B3" value="4.4" spread="1.5"/>
                    <measurement group_id="B4" value="4.4" spread="1.2"/>
                    <measurement group_id="B5" value="4.5" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Stool consistency</title>
          <description>7-point Bristol stool scale ranging from &quot;1&quot;= hard lumpy stool to &quot;7&quot;= watery, liquid stool</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.7" spread="0.6"/>
                    <measurement group_id="B2" value="5.7" spread="0.5"/>
                    <measurement group_id="B3" value="5.7" spread="0.6"/>
                    <measurement group_id="B4" value="5.7" spread="0.6"/>
                    <measurement group_id="B5" value="5.7" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>IBS-Symptom Severity Scale score</title>
          <description>IBS symptom severity score, ranging from &quot;0&quot;= no symptoms to &quot;500&quot;= very severe symptoms</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="343.4" spread="68.8"/>
                    <measurement group_id="B2" value="333.3" spread="78.3"/>
                    <measurement group_id="B3" value="332.6" spread="74.3"/>
                    <measurement group_id="B4" value="335.7" spread="69.4"/>
                    <measurement group_id="B5" value="336.3" spread="72.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>European Quality of Life Questionnaire 5D (EQ-5D) QoL VAS</title>
          <description>European quality of life visual analogue scale ranging from &quot;0&quot;= worst imaginable health state to &quot;100&quot;= best imaginable health state</description>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.5" spread="22.9"/>
                    <measurement group_id="B2" value="55.5" spread="21.9"/>
                    <measurement group_id="B3" value="58.1" spread="22.9"/>
                    <measurement group_id="B4" value="55.3" spread="22.3"/>
                    <measurement group_id="B5" value="55.8" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With Satisfactory Relief During 8 Weeks of Treatment (75% Rule); Intention-to-treat (ITT).</title>
        <description>Weekly binary questions (yes/no) from Interactive Voice/Web Response (IV/WRS) diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
        <time_frame>Eight weeks</time_frame>
        <population>Intention-to-Treat (559)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 1 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 3 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 6 Weeks With Satisfactory Relief During 8 Weeks of Treatment (75% Rule); Intention-to-treat (ITT).</title>
          <description>Weekly binary questions (yes/no) from Interactive Voice/Web Response (IV/WRS) diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
          <population>Intention-to-Treat (559)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders according to the 75% rule/&quot;Yes&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="55"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders according to the 75% rule/&quot;No&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95"/>
                    <measurement group_id="O2" value="92"/>
                    <measurement group_id="O3" value="84"/>
                    <measurement group_id="O4" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <groups_desc>Mantel-Haenszel-Test was used to compare separately each of the 3 active treatment groups with placebo using a two-sided overall significance level of 5%. The proportion of responders was tested with the following hypotheses: H0 (placebo) vs H1(Ibodutant:1mg/3mg/10mg). Approximately 80% power based on the assumptions: rate placebo 40%, expected mean therapeutic gain over placebo 15% for at least one dose of Ibodutant.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Multiplicity was adjusted by using the Hochberg Procedure.</p_value_desc>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 4 Weeks With Satisfactory Relief During 8 Weeks of Treatment (50% Rule) in the ITT Population</title>
        <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 4/8 weeks with at least 2 consecutive weeks of satisfactory relief during Week 5 to Week 8(50% rule)</description>
        <time_frame>Eight weeks</time_frame>
        <population>Intention-to-Treat (559)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 1 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 3 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort at the End of 8 Weeks of Treatment, Where the Response is Defined as at Least 4 Weeks With Satisfactory Relief During 8 Weeks of Treatment (50% Rule) in the ITT Population</title>
          <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 4/8 weeks with at least 2 consecutive weeks of satisfactory relief during Week 5 to Week 8(50% rule)</description>
          <population>Intention-to-Treat (559)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="140"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="139"/>
                <count group_id="O4" value="142"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders according to the 50% rule/&quot;Yes&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="61"/>
                    <measurement group_id="O3" value="74"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders according to the 50% rule/&quot;No&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="77"/>
                    <measurement group_id="O3" value="65"/>
                    <measurement group_id="O4" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <p_value_desc>Multiplicity was adjusted using the Hochberg procedure.</p_value_desc>
            <method>Mantel Haenszel</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Changes (Using EuroQoL EQ-5D Questionnaire)</title>
        <description>Change in EQ-5D Quality of Life (visual analogue scale) score at the end of 8 weeks of treatment versus baseline (at randomisation). EQ-5D quality of life visual analogue scale ranges from “0”= worst imaginable health state to “100”=best imaginable health state.</description>
        <time_frame>Eight weeks</time_frame>
        <population>Intention-to-treat; i.e. all ITT patients who provided EQ-5D data at Visit 2 (start of treatment) and Visit 4 (end of treatment).</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 1 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 3 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Changes (Using EuroQoL EQ-5D Questionnaire)</title>
          <description>Change in EQ-5D Quality of Life (visual analogue scale) score at the end of 8 weeks of treatment versus baseline (at randomisation). EQ-5D quality of life visual analogue scale ranges from “0”= worst imaginable health state to “100”=best imaginable health state.</description>
          <population>Intention-to-treat; i.e. all ITT patients who provided EQ-5D data at Visit 2 (start of treatment) and Visit 4 (end of treatment).</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
                <count group_id="O2" value="133"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (randomisation)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.4" spread="20.6"/>
                    <measurement group_id="O2" value="58.2" spread="22.0"/>
                    <measurement group_id="O3" value="57.2" spread="22.0"/>
                    <measurement group_id="O4" value="58.7" spread="21.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visit 4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.3" spread="17.2"/>
                    <measurement group_id="O2" value="72.1" spread="18.7"/>
                    <measurement group_id="O3" value="66.7" spread="20.7"/>
                    <measurement group_id="O4" value="72.2" spread="17.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subgroup Analysis: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort According to the 75% Rule in the Female ITT Population</title>
        <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
        <time_frame>Eight weeks</time_frame>
        <population>Intention-to-Treat in the female population (333)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 1 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 3 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Subgroup Analysis: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort According to the 75% Rule in the Female ITT Population</title>
          <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
          <population>Intention-to-Treat in the female population (333)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="89"/>
                <count group_id="O2" value="87"/>
                <count group_id="O3" value="79"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders according to 75% rule/&quot;Yes&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="35"/>
                    <measurement group_id="O3" value="37"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders according to 75% rule/&quot;No&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="52"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Subgroup Analysis: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort According to the 75% Rule in the Male ITT Population</title>
        <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
        <time_frame>Eight weeks</time_frame>
        <population>Intention-to-Treat in the male population (226)</population>
        <group_list>
          <group group_id="O1">
            <title>Ibodutant 1 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O2">
            <title>Ibodutant 3 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O3">
            <title>Ibodutant 10 mg</title>
            <description>oral tablet, once daily</description>
          </group>
          <group group_id="O4">
            <title>Placebo</title>
            <description>oral tablet, once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Subgroup Analysis: Response for Relief of Overall IBS Symptoms and of Abdominal Pain/Discomfort According to the 75% Rule in the Male ITT Population</title>
          <description>Weekly binary questions (yes/no) from IV/WRS diary records: &quot;Did you have satisfactory relief of your overall IBS symptoms during the last week?&quot; and &quot;Did you have satisfactory relief of your abdominal pain or discomfort during the last week?&quot;
Responder: Report of satisfactory overall IBS symptom relief =&quot;Yes&quot; and of satisfactory abdominal pain/discomfort relief = &quot;Yes&quot; 6/8 weeks (75% rule)</description>
          <population>Intention-to-Treat in the male population (226)</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="51"/>
                <count group_id="O2" value="51"/>
                <count group_id="O3" value="60"/>
                <count group_id="O4" value="64"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Responders according to the 75% rule/&quot;Yes&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Responders according to the 75% rule/&quot;No&quot;</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="42"/>
                    <measurement group_id="O4" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>8 weeks for Treatment Emergent Signs and Symptoms (TESS)</time_frame>
      <desc>TESS (collected from first drug intake at Visit 2 (randomisation) during the treatment period of 8 weeks) were analysed for the Safety Population (all patients who took at least one dose of study medication, N = 565).
Generally, Adverse Events were reported/patient for a period of 12 weeks (during the total individual study period).</desc>
      <group_list>
        <group group_id="E1">
          <title>Ibodutant 1 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="E2">
          <title>Ibodutant 3 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="E3">
          <title>Ibodutant 10 mg</title>
          <description>oral tablet, once daily</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>oral tablet, once daily</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Mydriasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Worsened Abdominal Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Acute Appendicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus type II</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterus Myomatosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="141"/>
                <counts group_id="E2" subjects_affected="19" subjects_at_risk="142"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="139"/>
                <counts group_id="E4" subjects_affected="20" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="141"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="141"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="142"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood Creatine Phosphokinase Increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="141"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="142"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="143"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="141"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="142"/>
                <counts group_id="E3" events="11" subjects_affected="8" subjects_at_risk="139"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="143"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to submitting the results of this study for publication or presentation, the PI will allow Sponsor at least 60 days time to review and comment upon the publication manuscript. No publication of PI is permitted before the overall publication of the multicentre study made by the Sponsor (or its designee), unless said overall publication is not made within 18 months from the completion of the Final Study Report.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Angela Capriati MD PhD, Corporate Director of Clinical Research</name_or_title>
      <organization>Menarini Ricerche S.p.A.</organization>
      <phone>+39 055 5680 ext 9933</phone>
      <email>acapriati@menarini-ricerche.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

